Publications

Journal Article Epublish 4 citations
Electronic publication date
August 8, 2021

View on Pubmed.gov 34359600 | View on doi.org 10.3390/cancers...

Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor.

Search for publications in this journal Cancers (Basel)

Abstract

The majority of gastrointestinal stromal tumor (GIST) patients develop resistance to the first-line KIT inhibitor, imatinib mesylate (IM), through acquisition of secondary mutations in KIT or bypass signaling pathway activation. In addition to KIT, AKT is a relevant target for inhibition, since the PI3K/AKT pathway is crucial for IM-resistant GIST survival. We evaluated the activity of a novel pan-AKT inhibitor, MK-4440 (formerly ARQ 751), as monotherapy and in combination with IM in GIST cell lines and preclinical models with varying IM sensitivities. Dual inhibition of KIT and AKT demonstrated synergistic effects in IM-sensitive and -resistant GIST cell lines. Proteomic analyses revealed upregulation of the tumor suppressor, PDCD4, in combination treated cells. Enhanced PDCD4 expression correlated to increased cell death. In vivo studies revealed superior efficacy of MK-4440/IM combination in an IM-sensitive preclinical model of GIST compared with either single agent. The combination demonstrated limited efficacy in two IM-resistant models, including a GIST patient-derived xenograft model possessing an exon 9 KIT mutation. These studies provide strong rationale for further use of AKT inhibition in combination with IM in primary GIST; however, alternative agents will need to be tested in combination with AKT inhibition in the resistant setting.

References

Int J Mol Sci. 2020 Nov 22;21(22):

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8448-E8457

Drugs. 2020 Jul;80(11):1133-1138

Clin Cancer Res. 2013 Feb 1;19(3):620-30

Cited by 4 citations (total)

Journal Article Review

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.

Electronic publication date November 6, 2024

Search for publications in this journal Curr Treat Options Oncol

Chunxiao He [...] Xi Xiang et al.

Gastrointestinal stromal tumor (GIST) is characterized by well-defined oncogenes. Despite the significant improvement in treatment outcomes with adjuvant imatinib therapy...

Journal Article

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway.

Electronic publication date February 21, 2025

Search for publications in this journal Clin Transl Med

Chunxiao He [...] Xi Xiang et al.

BACKGROUND

Most gastrointestinal stromal tumours (GISTs) are driven by KIT proto-oncogene, receptor tyrosine kinase (KIT). Targeted treatment with imatinib has been...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties